That would imply roughly a $20B EV, or around $80–90/share depending on future debt levels and dilution/buybacks.
That implies roughly a ~30% share price CAGR from today’s ~$25 levels through 2030, an r/r profile I’m willing to take. $HIMS
English
Brill Research
19.5K posts
Brill Research
@BrillResearch
Investment theses backed by deep fundamental & technical analysis | 𝐈𝐧𝐪𝐮𝐢𝐫𝐢𝐞𝐬: [email protected]
Katılım Ağustos 2018
60 Takip Edilen2.6K Takipçiler
$HIMS reported a weak Q1, but still raised FY26 revenue and EBITDA guidance while reiterating its 2030 ambition of $1.3B+ EBITDA. At a conservative and reasonable 15x EV/EBITDA multiple (considering continued double-digit growth across revenue, EPS, and EBITDA).
English
$VKTX seems like this one is setting up for a massive move. Price action keeps tightening and flagging on the monthly chart, looks like pressure is building for a potential breakout.
English
Currently holding both — trading swings in $MRNA while positioned long in $BNTX for a potentially explosive re-rating if the oncology pipeline delivers.
English
$MRNA trading at ~2x the EV of $BNTX is an interesting setup.
While $BNTX’s current oncology pipeline arguably looks more promising, its massive cash reserves should comfortably fund pipeline expansion, clinical progress, and future BD opportunities.
English
$BNTX sitting on ~$19.7B in cash (current FX) with promising clinical progress for pumitamig. Still a waiting game until oncology launches materialize. A $1 billion SRP feels premature — better to deploy that capital into BD or keep it in yield-generating securities to fund R&D.
English
$VKTX Viking Therapeutics Price Target Maintained With a $125.00/Share by BTIG
English
$CUV: Jefferies sets a A$39 PT vs ~A$9 current SP. Cash-rich, profitable biotech with a major catalyst ahead. If vitiligo hits, 5–10x upside looks reasonable. Recently added to my position and plan to scale in more while it stays under A$10.
English
I still see upside in $CYDVF as a lithium play. A domestic Nevada asset looks increasingly strategic as geopolitical pressures rise. After-tax NPV > $4B and ~$4.3k/t opex vs. spot > $25k/t are compelling. But financing remains the key overhang, what’s holding it back?@CacosSpiros
English
$HIMS is starting to pay off nicely. Not to forget the 30% short float, which always gives potential for explosive moves.
Brill Research@BrillResearch
I just doubled my $HIMS position here. Playing the 2030's game.
English
$VKTX $MRNA remain my top 2 high potential short squeeze biotech plays. Both around 20% short float with operational catalysts.
English
I'm swinging $MRNA and holding $BNTX for a medium-to-longer term. The current discrepancy in EV is insane. I definitely see more value in $BNTX right now overall, thanks to its de-risked pipeline (BMS collab), cash position, and burn rate.
English
To cite Barron's: "With its ample cash position, BioNTech seems like an inexpensive bet on that pipeline even with the founders leaving the scene."
English
$BNTX trading at a $4 billion EV seems astonishingly cheap and could attract some takeover interest as biotechs heat up in the market. It has a $20 billion cash position, a cash-cow COVID business with $2 billion in expected revenue this year, and is catalyst-rich.
English
$PYPL — the question is what price it will be. My cost basis is around $90/share, and I see fair value over $100/share. An acquisition seems likely to land in the $60–80 range, as those prices would already represent a significant premium to current levels.
English
$MRNA $55 is a nice weekly breakout level here. 20% of the float is sold short; quite nice positive momentum lately following the FDA's change of course. $55–60 breakout could lead to a nice swing back to ~$100 on continued positive momentum.
Brill Research@BrillResearch
$MRNA swing is on the edge of turning green. Critical spot on the weekly chart here; 20% short float and massively oversold in 2025; could be a nice comeback story in 2026 around $60+.
English
$CYDVF Century Lithium Reports Updated Feasibility Study With After-Tax NPV Of $4.01 Billion And Operating Costs Of $4,389 Per Tonne Of Lithium Carbonate For The Angel Island Lithium Project, Nevada; over $1 billion higher than in PFS etc. back in 2024
English
I just doubled my $HIMS position here. Playing the 2030's game.
English
$BNTX has been moving sideways for over four years. I believe we will see a substantial trend change in the next 12–24 months as the pipeline develops with many promising market-reaching drugs. $BNTX plans 15 Phase 3 trials by eoy and has over $18 bn in cash to fund further R&D.
English
@victor_privin I am very convinced of this. $BNTX should only be a matter of time once we see a sustainable breakout from the basing range and a sustainable uptrend driven by operational success as more products reach the market.
English
$MRNA there she goes, breaking through some critical weekly resistance areas—up 16% for the day! Swing looking better and better.
Brill Research@BrillResearch
$MRNA swing is on the edge of turning green. Critical spot on the weekly chart here; 20% short float and massively oversold in 2025; could be a nice comeback story in 2026 around $60+.
English